Mylan (NASDAQ:MYL) had its price target increased by UBS Group from $17.00 to $18.00 in a report published on Tuesday, BenzingaRatingsTable reports. The firm currently has a neutral rating on the stock.
Several other brokerages have also issued reports on MYL. Piper Sandler lowered their target price on Mylan from $23.00 to $17.00 and set a neutral rating for the company in a research report on Wednesday, April 15th. Royal Bank of Canada reiterated a buy rating and set a $26.00 price target on shares of Mylan in a report on Tuesday, May 12th. TheStreet upgraded Mylan from a d+ rating to a c rating in a report on Thursday, August 6th. Wells Fargo & Co decreased their price target on Mylan from $23.00 to $18.00 and set an equal weight rating for the company in a report on Thursday, April 30th. Finally, BidaskClub downgraded Mylan from a hold rating to a sell rating in a report on Thursday, July 23rd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The company has an average rating of Hold and an average target price of $20.67.
NASDAQ:MYL traded up $0.01 during trading hours on Tuesday, hitting $16.15. 82,611 shares of the company were exchanged, compared to its average volume of 6,637,100. The stock has a market capitalization of $8.67 billion, a price-to-earnings ratio of 30.49, a price-to-earnings-growth ratio of 1.74 and a beta of 1.53. The company has a current ratio of 0.93, a quick ratio of 0.53 and a debt-to-equity ratio of 0.84. Mylan has a one year low of $12.75 and a one year high of $23.11. The company has a fifty day simple moving average of $16.27 and a 200 day simple moving average of $17.03.
Several institutional investors and hedge funds have recently modified their holdings of MYL. Massachusetts Financial Services Co. MA lifted its position in shares of Mylan by 2.7% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,842,968 shares of the company’s stock worth $27,479,000 after buying an additional 48,693 shares in the last quarter. Treasurer of the State of North Carolina grew its position in Mylan by 66.9% in the first quarter. Treasurer of the State of North Carolina now owns 220,508 shares of the company’s stock worth $3,288,000 after acquiring an additional 88,380 shares in the last quarter. Rhumbline Advisers grew its position in Mylan by 11.7% in the first quarter. Rhumbline Advisers now owns 796,519 shares of the company’s stock worth $11,876,000 after acquiring an additional 83,172 shares in the last quarter. AXA purchased a new position in Mylan in the first quarter worth $12,491,000. Finally, Royal Bank of Canada grew its position in Mylan by 48.0% in the first quarter. Royal Bank of Canada now owns 258,397 shares of the company’s stock worth $3,852,000 after acquiring an additional 83,822 shares in the last quarter. Institutional investors own 85.58% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More: Reverse Stock Split
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.